To examine selegiline's dosing effects, we studied 16 Parkinson disease patients with motor fluctuations in a double-blind, crossover trial of selegiline at 0, 5, and 10 mg daily. Patients' motor diaries, disability scores, and walking speed were marginally improved, with no advantage of 10 mg over 5 mg found. We conclude that in patients with motor fluctuations, selegiline provides modest symptomatic effects, with daily dosing of 5 mg being indistinguishable from 10 mg.